당뇨병 치료제 시장 규모, 점유율, 성장 분석 : 당뇨병 유형별, 약제 유형별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Diabetes Therapeutics Market size was valued at USD 76.11 Billion in 2024 and is poised to grow from USD 81.36 Billion in 2025 to USD 138.76 Billion by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

The global diabetes therapeutics market is experiencing robust growth driven by an increasing prevalence of diabetes, innovative treatment advancements, and evolving healthcare dynamics. A rising aging population presents significant opportunities, as older individuals are more susceptible to diabetes. Urbanization and lifestyle changes further amplify diabetes risks, contributing to market expansion. Growing awareness and early diagnosis enhance the adoption of diabetes therapies, while the trend towards personalized medicine allows for tailored treatment solutions that improve efficacy. Technological integration, including AI, machine learning, and IoT, revolutionizes drug discovery, patient monitoring, and disease management. Additionally, blockchain technology ensures secure handling of patient records, fostering trust and regulatory compliance. Augmented and virtual reality are employed for patient education, supporting healthier lifestyle choices and improved treatment adherence.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetes Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Diabetes Therapeutics Market Segments Analysis

Global Diabetes Therapeutics Market is segmented by Diabetes Type, Drug Type, End User and region. Based on Diabetes Type, the market is segmented into Type 1 Diabetes, Type 2 Diabetes and Gestational Diabetes. Based on Drug Type, the market is segmented into Oral Antidiabetics and Injectable Antidiabetics. Based on End User, the market is segmented into Hospitals, Clinics and Personal Use. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Diabetes Therapeutics Market

The growing incidence of diabetes, encompassing both type 1 and type 2, is driving sustained demand within the diabetes therapeutics market. Additionally, the increasing number of elderly individuals globally contributes to this trend, as older adults are more susceptible to developing diabetes. Furthermore, the rise in obesity rates, coupled with sedentary lifestyles and unhealthy dietary choices, exacerbates the situation, leading to higher levels of insulin resistance and related metabolic disorders. Collectively, these factors are propelling the expansion of the diabetes therapeutics market, highlighting the urgent need for effective treatment options to address this widespread health challenge.

Restraints in the Global Diabetes Therapeutics Market

The Global Diabetes Therapeutics market faces considerable challenges due to the high costs associated with managing both type 1 and type 2 diabetes. Lifelong treatment often necessitates the use of insulin, various medications, therapies, and glucose monitoring devices, which can be prohibitively expensive for individuals lacking medical insurance or with inadequate healthcare coverage. This financial burden makes it difficult for many to access the necessary diabetes therapeutics, particularly in the absence of reimbursement options. Furthermore, escalating prices of novel biologics and personalized medicine are hindering innovation within the diabetes therapeutics sector, exacerbating the issues faced by patients and healthcare providers alike.

Market Trends of the Global Diabetes Therapeutics Market

The Global Diabetes Therapeutics market is increasingly embracing personalized and precision medicine approaches, reflecting a significant trend towards tailored treatments that cater to individual genetic profiles, metabolic patterns, and lifestyle factors. This shift aims to address the underlying causes of diabetes, enhancing treatment efficacy by effectively reducing insulin resistance. The growing emphasis on personalized solutions not only aims to improve patient outcomes but also fosters a more patient-centric healthcare landscape. Furthermore, the increasing affordability and improved accessibility of these advanced therapies contribute to their rising popularity, facilitating broader adoption among diverse patient populations and driving sustained growth in the diabetes therapeutics sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Diabetes Therapeutics Market Size by Diabetes Type & CAGR (2026-2033)

• Market Overview
• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

Global Diabetes Therapeutics Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Oral Antidiabetics
• Injectable Antidiabetics

Global Diabetes Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Personal Use

Global Diabetes Therapeutics Market Size & CAGR (2026-2033)

• North America (Diabetes Type, Drug Type, End User)
  • US
  • Canada
• Europe (Diabetes Type, Drug Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diabetes Type, Drug Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diabetes Type, Drug Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diabetes Type, Drug Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations